Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors
© 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH..
CYP121 of Mycobacterium tuberculosis (Mtb) is an essential target for the development of novel potent drugs against tuberculosis (TB). Besides known antifungal azoles, further compounds of the azole class were recently identified as CYP121 inhibitors with antimycobacterial activity. Herein, we report the screening of a similarity-oriented library based on the former hit compound, the evaluation of affinity toward CYP121, and activity against M. bovis BCG. The results enabled a comprehensive SAR study, which was extended through the synthesis of promising compounds and led to the identification of favorable features for affinity and/or activity and hit compounds with 2.7-fold improved potency. Mode of action studies show that the hit compounds inhibit substrate conversion and highlighted CYP121 as the main antimycobacterial target of our compounds. Exemplified complex crystal structures of CYP121 with three inhibitors reveal a common binding site. Engaging in both hydrophobic interactions as well as hydrogen bonding to the sixth iron ligand, our compounds block a solvent channel leading to the active site heme. Additionally, we report the first CYP inhibitors that are able to reduce the intracellular replication of M. bovis BCG in macrophages, emphasizing their potential as future drug candidates against TB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
ChemMedChem - 16(2021), 18 vom: 16. Sept., Seite 2786-2801 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Walter, Isabell [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2022 Date Revised 03.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cmdc.202100283 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325601984 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325601984 | ||
| 003 | DE-627 | ||
| 005 | 20240403232335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cmdc.202100283 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM325601984 | ||
| 035 | |a (NLM)34010508 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Walter, Isabell |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-Activity Relationship and Mode-Of-Action Studies Highlight 1-(4-Biphenylylmethyl)-1H-imidazole-Derived Small Molecules as Potent CYP121 Inhibitors |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2022 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. ChemMedChem published by Wiley-VCH GmbH. | ||
| 520 | |a CYP121 of Mycobacterium tuberculosis (Mtb) is an essential target for the development of novel potent drugs against tuberculosis (TB). Besides known antifungal azoles, further compounds of the azole class were recently identified as CYP121 inhibitors with antimycobacterial activity. Herein, we report the screening of a similarity-oriented library based on the former hit compound, the evaluation of affinity toward CYP121, and activity against M. bovis BCG. The results enabled a comprehensive SAR study, which was extended through the synthesis of promising compounds and led to the identification of favorable features for affinity and/or activity and hit compounds with 2.7-fold improved potency. Mode of action studies show that the hit compounds inhibit substrate conversion and highlighted CYP121 as the main antimycobacterial target of our compounds. Exemplified complex crystal structures of CYP121 with three inhibitors reveal a common binding site. Engaging in both hydrophobic interactions as well as hydrogen bonding to the sixth iron ligand, our compounds block a solvent channel leading to the active site heme. Additionally, we report the first CYP inhibitors that are able to reduce the intracellular replication of M. bovis BCG in macrophages, emphasizing their potential as future drug candidates against TB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CYP121 | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a biological activity | |
| 650 | 4 | |a complex structures | |
| 650 | 4 | |a structure-activity relationships | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Small Molecule Libraries |2 NLM | |
| 650 | 7 | |a cytochrome P-450 CYP121 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme System |2 NLM | |
| 650 | 7 | |a 9035-51-2 |2 NLM | |
| 700 | 1 | |a Adam, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Gentilini, Maria Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Kany, Andreas M |e verfasserin |4 aut | |
| 700 | 1 | |a Brengel, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Thomann, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Sparwasser, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Köhnke, Jesko |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Rolf W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemMedChem |d 2006 |g 16(2021), 18 vom: 16. Sept., Seite 2786-2801 |w (DE-627)NLM164619577 |x 1860-7187 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:18 |g day:16 |g month:09 |g pages:2786-2801 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cmdc.202100283 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 18 |b 16 |c 09 |h 2786-2801 | ||